Comment from ICON Clinical Research

Summary: ICON Clinical Research, LLC expresses strong support for the FDA's Expedited Investigational New Drug Pilot Program, noting its potential to improve IND submission quality and efficiency. The company recommends specific criteria for Qualified Research Institution (QRI) qualification, the use of structured risk-benefit assessment frameworks, and the development of standardized review templates and manuals.